Search

Begin New Search Topic Health Political Geography United States of America

1. California Wildfires and Planetary Health

Author:
Pey Peili
Publication Date:
01-2025
Content Type:
Commentary and Analysis
Institution:
Centre for Non-Traditional Security Studies, S. Rajaratnam School of International Studies
Abstract:
The California wildfires are an environmental disaster, but they also point to a deeper set of challenges, not only for the United States of America but for the global community. Such wildfires, which are ever-increasing in frequency and scale due to the impact of climate change, result in structural damage and long-term health risks that disproportionately affect vulnerable communities and are a costly burden to the state. A planetary health approach highlights the need for a more comprehensive understanding of the climate-environment-health interface in managing the risk and incidence of wildfires.
Topic:
Climate Change, Health, Natural Disasters, and Wildfires
Political Geography:
California, North America, and United States of America

2. 'I Don't Know What Tomorrow will Bring': Understanding COVID-19’s Impact on the United States’ Stateless Population

Author:
Ashley Walters, Taryn Painter, and Heidi Meyers
Publication Date:
02-2024
Content Type:
Journal Article
Journal:
Statelessness & Citizenship Review
Institution:
Peter McMullin Centre on Statelessness, Melbourne Law School
Abstract:
In March 2020, COVID-19 was declared by the World Health Organisation (‘WHO’) as a global pandemic. Since the WHO’s declaration, it has become increasingly clear that the most vulnerable communities have experienced the brunt of the pandemic. Though race, ethnicity and economic status are considered in a majority of reports on the social, physical and financial impacts of COVID-19, there is little to no information on the impact of COVID-19 on stateless communities within the United States (‘US’). This research endeavours to add to the understanding of statelessness in the US by determining the impacts of COVID-19 on stateless people in the US through a survey scoping project. Through anonymous questionnaires completed by stateless individuals (n=19) in the United States, this study explores how stateless individuals have been impacted by the pandemic, including experiencing economic hardships, mental health challenges, physical health concerns and issues with documentation and legal status.
Topic:
Health, Economy, Mental Health, Pandemic, COVID-19, Stateless Population, Vulnerability, Legal Status, and Documentation
Political Geography:
North America and United States of America

3. Extreme Heat Is More Dangerous for Workers Every Year

Author:
Jill Rosenthal, Rosa Barrientos-Ferrer, and Kate Petosa
Publication Date:
06-2024
Content Type:
Special Report
Institution:
Center for American Progress - CAP
Abstract:
Federal and state governments should step up efforts—including adopting heat standards—to address increased on-the-job heat-related injury, illness, and death.
Topic:
Climate Change, Health, Labor Issues, Regulation, and Heat Waves
Political Geography:
Global Focus and United States of America

4. Considering Returns on Federal Investment in the Negotiated “Maximum Fair Price” of Drugs Under the Inflation Reduction Act: an Analysis

Author:
Edward W. Zhou, Paula G. da Silva, Debbie Quijada, and Fred D. Ledley
Publication Date:
03-2024
Content Type:
Working Paper
Institution:
Institute for New Economic Thinking (INET)
Abstract:
The Inflation Reduction Act (IRA) of 2022 contained landmark provisions authorizing government to negotiate a “maximum fair price” for selected Medicare Part D drugs considering the manufacturer’s research and development costs, federal support for discovery and development, the extent to which the drugs address unmet medical needs, and other factors. This working paper describes federal investment in the discovery and development of the ten drugs selected for price negotiation in the first year of the IRA as well as the health value created through Medicare Part D spending on these drugs. We identified $11.7 billion in NIH funding for basic or applied research leading to approval of these drugs with median investment costs of $895.4 million/drug. This early public investment provided a median cost savings to industry of $1,485 million/drug, comparable to reported levels of investment by industry. From 2017-2021, Medicare Part D spent $126.4 billion (median $10.7 billion) for these products before rebates. Excluding two products for diabetes, Medicare Part D spending was $97.4 billion and the total health value created was 650,940 QALYs or $67.7 billion (WTP/QALY=$104K) representing a negative residual health value of -$29.7 billion (before rebates). We argue that a negotiated fair price should provide returns on both private and public investments in these products commensurate with the scale and risk of these investments, with the principal return on public sector investments being the residual health value (net price) accruing to those using the product. These empirical data provide a cost basis for negotiating a fair price that rewards early government investments in innovation and provides social value for the public.
Topic:
Economics, Health, Public Health, Pharmaceuticals, and Public Investment
Political Geography:
North America and United States of America

5. Implications of the Inflation Reduction Act for the Biotechnology Industry

Author:
Cody Hyman, Henry Dao, Gregory Vaughan, and Fred D. Ledley
Publication Date:
07-2024
Content Type:
Working Paper
Institution:
Institute for New Economic Thinking (INET)
Abstract:
The Inflation Reduction Act of 2022 contains landmark provisions authorizing the government to negotiate the price of selected drugs covered by Medicare Part D. The biopharmaceutical industry has criticized these provisions as a threat to innovation arguing that reducing future revenues could disincentivize equity investment in biotechnology. This research examines the sensitivity of private and public equity investment in the biotechnology industry to drug price indices and market conditions from 2000-2022. The analysis shows that equity financing and valuation in the biotechnology industry were strongly associated with equity market conditions but not indices of either producer or consumer drug prices. These results do not support claims of an association between changing drug prices and the availability of equity capital to emerging biotechnology companies, which currently sponsor the majority of all clinical trials. These results add to evidence that the IRA may not have a negative impact on pharmaceutical innovation.
Topic:
Economics, Health, Inflation, Innovation, Biotechnology, Public Investment, and Inflation Reduction Act
Political Geography:
North America and United States of America

6. Setting Pharmaceutical Drug Prices: What the Medicare Negotiators Need to Know About Innovation and Financialization

Author:
Öner Tulum and William Lazonick
Publication Date:
09-2024
Content Type:
Working Paper
Institution:
Institute for New Economic Thinking (INET)
Abstract:
Mandated by the Inflation Reduction Act of 2022, the U.S. government through the Centers for Medicare and Medicaid Services (CMS) is negotiating with pharmaceutical companies over the “maximum fair price” of ten drugs in wide use by Medicare patients. Over the next few years, the number of drugs whose prices are subject to negotiations will increase. The pharmaceutical companies contend that a “fair” price would be a “value-based price” that enables the companies’ shareholders to capture the value that the drug creates for society. Invoking the dominant “maximizing shareholder value” ideology, the argument for value-based pricing assumes that it is only a pharmaceutical company’s shareholders who make the risky investments that fund drug innovation. Pharmaceutical executives and their lobbyists warn that a lowering of drug prices will reduce investments in new drugs. The purpose of this paper is to enable CMS negotiators to respond to these arguments by showing a) why drug-price regulation is required, given the relation between scale economies in supplying drugs and price inelasticity of drug demand; b) how the pharmaceutical companies with which they are negotiating prices are, in general, not using their profits from unregulated drug prices to fund drug innovation but rather to fund distributions to shareholders in the form of cash dividends and stock buybacks; c) that publicly listed pharmaceutical companies do not typically rely upon investment by shareholders to fund drug innovation; and d) that investment in drug innovation entails “collective and cumulative learning” in foundational and translational research that is both antecedent and external to the investments in clinical research that a pharmaceutical company may make to bring a safe and effective drug to market.
Topic:
Economics, Health, Finance, Innovation, Pharmaceuticals, and Medicare
Political Geography:
North America and United States of America

7. Prioritizing Health System Development in the Pacific: A Layered Approach

Author:
Kathryn Paik and Eileen Natuzzi
Publication Date:
07-2024
Content Type:
Policy Brief
Institution:
Center for Strategic and International Studies (CSIS)
Abstract:
This brief gives an overview of health challenges across the Pacific Islands region and identifies the need for development partners such as the United States to reframe their approach to health system development. The document provides several recommendations for policymakers and development organizations as they work with the Pacific to effectively meet the health needs of the region.
Topic:
Development, Health, and Sustainability
Political Geography:
Asia-Pacific and United States of America

8. U.S. Health Care from a Global Perspective, 2022: Accelerating Spending, Worsening Outcomes

Author:
Munira Z. Gunja, Evan D. Gumas, and Reginald D. Williams II
Publication Date:
01-2023
Content Type:
Policy Brief
Institution:
Commonwealth Fund
Abstract:
In the previous edition of U.S. Health Care from a Global Perspective, we reported that people in the United States experience the worst health outcomes overall of any high-income nation.1 Americans are more likely to die younger, and from avoidable causes, than residents of peer countries. Between January 2020 and December 2021, life expectancy dropped in the U.S. and other countries.2 With the pandemic a continuing threat to global health and well-being, we have updated our 2019 cross-national comparison of health care systems to assess U.S. health spending, outcomes, status, and service use relative to Australia, Canada, France, Germany, Japan, the Netherlands, New Zealand, Norway, South Korea, Sweden, Switzerland, and the United Kingdom. We also compare U.S. health system performance to the OECD average for the 38 high-income countries for which data are available. The data for our analysis come from the Organisation for Economic Co-operation and Development (OECD) and other international sources (see “How We Conducted This Study” for details). For every metric we examine, we used the latest data available. This means that results for certain countries may reflect the height of the COVID-19 pandemic, when mental health conditions were surging, essential health services were disrupted, and patients may not have received the same level of care
Topic:
Health, Health Care Policy, Inequality, and Finance
Political Geography:
North America and United States of America

9. The Guinea Worm, President Carter and Me: A Journey Through Health Diplomacy

Author:
Lisa Rotondo
Publication Date:
05-2023
Content Type:
Journal Article
Journal:
American Diplomacy
Institution:
American Diplomacy
Abstract:
In September 2001, just days before 9/11, I arrived in Pissila, Burkina Faso for my Peace Corps assignment. I was eager to get to work helping my new home community do surveillance for a neglected tropical disease (NTD) called dracunculiasis, or Guinea worm disease. As a Peace Corps Volunteer in rural Burkina Faso, I biked from village to village, asking community members if they were aware of anyone with Guinea worm disease, an infection that has impacted both humans and animals since ancient times. Thanks, in part, to the work of volunteers before me, I never actually saw a person with Guinea worm disease during my two years as a volunteer. Burkina Faso was on the brink of eliminating the disease, and I remember thinking that the children in my community would never know the word for Guinea worm in their language, Moorè; it would not be in their vocabulary because they would never have to worry about it. I’ve reflected on that more than once during my career in public health. Knowing that we are truly making diseases history has been the drive underlying my efforts for the last two decades.
Topic:
Diplomacy, Health, Memoir, and Public Health
Political Geography:
Africa, United States of America, and Burkina Faso

10. Abortion Attitudes in a Post-Roe World: Findings From the 50-State 2022 American Values Atlas

Author:
PRRI Staff
Publication Date:
02-2023
Content Type:
Special Report
Institution:
PRRI: Public Religion Research Institute
Abstract:
In late June 2022, the Supreme Court’s decision in Dobbs v. Jackson overturned Roe v. Wade, reversing nearly five decades of precedent that had established a national right to abortion access. Republican-majority legislatures in several states had been chipping away at abortion rights for the past several years through increasingly strict regulations, but the Dobbs decision suddenly changed the policy landscape regarding reproductive rights, catapulting abortion to the forefront of American politics. The immediate impact of repealing Roe v. Wade was that control over abortion law reverted to the states. Some states had “trigger laws” in place to immediately impose abortion restrictions in the event that Roe was overturned, while others had protections in place to keep abortion policy as it was under Roe. In other states, lawmakers went to work crafting legislation in response to Dobbs. As of January 2023, the New York Times reports, 13 states have full abortion bans, some of which allow for exceptions if the life of the mother is in danger and in cases of rape or incest, and Georgia has a 6-week ban in place.[1] According to the Guttmacher Institute, abortion-access laws vary widely in the rest of the country, but all other states allow abortions at least up to 15 weeks into pregnancy.[2] Some state abortion laws have been challenged in court, and access has changed as court orders blocking or allowing restrictions have been put in place or lifted. Republicans in some states have made efforts to restrict reproductive rights a step further, pushing legislation that would limit people’s ability to receive abortion pills by mail or cross state lines to get abortion services, and would even label some forms of birth control as abortifacients.[3] Beginning in March 2022 and throughout the rest of the year, PRRI surveyed Americans about their views on abortion legality and related issues as part of our American Values Atlas. The scope of the project allows us to report results on some questions for all 50 states and the District of Columbia. In general, we found that most Americans support abortion legality in most or all cases and oppose the overturn of Roe. This report delves into the political, religious, and demographic correlates of various opinions on abortion access.
Topic:
Health, Politics, Religion, Survey, Reproductive Health, and Abortion
Political Geography:
North America and United States of America